Applied StemCell, Inc. (“ASC”), a genome engineering company with deep expertise in induced pluripotent stem cell (iPSC) technology and Cellipont Bioservices, a cell therapy contract development and ...

As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and ...

Aspen's sasineprocel is an autologous induced pluripotent stem cell (iPSC) derived dopaminergic neuron precursor cell (DANPC) ...

Orphan designation reflects unmet need in RP rather than evidence of efficacy, while offering development incentives and ...

Japan’s health ministry has endorsed the first stem-cell therapy derived from induced pluripotent stem cells (iPSCs) for ...

Three lines of GMP iPS Cells derived from type O female blood are now offered as off-the-shelf product It is well known that HLA homozygous iPSCs are often selected to reduce adverse immune response ...

The blood-brain barrier protects the central nervous system by tightly regulating what crosses between the two compartments. Neurons are vulnerable if the barrier suffers damage or weakens with age, ...

Induced pluripotent stem cells (iPSCs) are a “starting material grail” for advanced therapies. That’s according to Sven Kili, chief development officer at CCRM, the Canadian regenerative medicine ...

Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...

Japan’s move to conditionally approve two induced pluripotent stem cell derived therapies marks a significant development for ...